At this time, posts about Isu Abxis are rapidly increasing on portals and securities communities. Today, foreigners have tentatively sold a net 3,000 shares of Isu Abxis, and institutions have sold a net 33,000 shares. Isu Abxis is known as a subsidiary of the Isu Group, developing antibiotic treatments and providing medical services.
As of 1:30 PM on the 9th, the stock price of Isu Abxis is 10,050 KRW, down 13.36% from the previous day, with a trading volume of 3,809,360 shares, which is about 36.87% of the 5-day average trading volume. On March 5, Isu Abxis became a market issue with the news "Gaucher disease treatment Abcertin completes Phase 1 clinical trial... stock price rises."
In addition to Isu Abxis, posts by investors are rapidly increasing for Bident (121800), KTH (036030), and Baekkwang Industry (001340).
※Source: AI Investment Assistant AI Lassiro
※ This article was generated in real-time by an article auto-generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
